Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can estrogen therapy improve cholesterol and blood sugar control in women with low hormone levels?

NCT ID NCT07821086

Symptom relief Sponsor: Khyber Medical University Peshawar Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are studying whether three months of estrogen therapy changes cholesterol levels and insulin sensitivity in women with hypogonadism, a condition where the ovaries produce little or no estrogen. Thirty women aged 18 to 50 will receive estrogen as a pill or skin patch. The team will measure cholesterol, fasting glucose, fasting insulin, and a marker of insulin resistance before treatment and again after three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
estrogen therapy, given as estradiol valerate by mouth or through the skin
What this could lead to
If estrogen therapy improves cholesterol and insulin sensitivity, it could support better metabolic monitoring and treatment choices for women with hypogonadism.
What could go wrong
This is a small, single-group study with no comparison group, so any changes seen could be due to other factors. Estrogen therapy carries known risks, including blood clots, and is not safe for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18 to 50 years. * Diagnosis of hypogonadism, including: * Primary ovarian insufficiency (POI) * Hypogonadotropic hypogonadism * Early menopause Exclusion Criteria: * Contraindications to estrogen therapy, including a history of thromboembolic events or certain hormone-sensitive cancers. * Pre-existing conditions that may significantly affect lipid metabolism or insulin sensitivity. * Use of medications known to affect lipid metabolism or insulin sensitivity. * Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Female hypogonadism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Female hypogonadism

Contacts and locations

Locations

  • Institute of Basic Medical Sciences

    Peshawar, Khyber Pakhtunkhwa, 25100, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.